Ohio State University spinout Entrada Therapeutics has pocketed $116m in a series B round.
Entrada Therapeutics, a US-based drug delivery platform developer spun out of Ohio State University, secured $116m in its series B round today led by Wellington Management.
Roche Venture Fund and MRL Ventures Fund, respective vehicles for pharmaceutical firms Roche and Merck & Co, also took part in the round together with CureDuchenne Ventures, the investment arm of nonprofit CureDuchenne.
Redmile Group, TCG Crossover, Greenspring Associates, Point72, Moore Strategic Ventures, Qatar Investment Authority, Goldman Sachs, 5AM Ventures, MPM Capital, Agent Capital and an unnamed investment firm filled out the round.
Founded in 2016, Entrada has developed intracellular technology intended to help medicines access both small and large cells in order to treat genetic diseases. The funding will allow Entrada to advance its pipeline to the clinic.
Entrada raised $59m in series A funding co-led by MPM Capital and 5AM Ventures in 2018, when MRL Ventures Fund, Roche Venture Fund and Agent Capital also invested.
Entrada had secured an undisclosed amount of seed financing from 5AM, Roche Venture Fund and MRL Ventures Fund.
– A version of this article first appeared on our sister site, Global Corporate Venturing.
